1-3 of 3
Eric Masson, PharmD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Exposure-Response of the Bruton Tyrosine Kinase Inhibitor, Acalabrutinib, in the Treatment of Hematologic Malignancies

Feng Jin, PhD, Ming Yin, PhD, Vinay Mandava, Helena Edlund, PhD, Marilee Andrew, PhD, Priti Patel, MD, Eric Masson, PharmD, Nidal Al-Huniti, PhD, Xiaolin Wang, ScD, J. Greg Slatter, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1268.
https://doi.org/10.1182/blood.V130.Suppl_1.1268.1268
Published: 2017
Journal Articles

Population Pharmacokinetics of Bruton Tyrosine Kinase Inhibitor, Acalabrutinib, in Healthy Volunteers and Patients with B-Cell Malignancies

Helena Edlund, PhD, Marilee Andrew, PhD, Feng Jin, PhD, Priti Patel, MD, Eric Masson, PharmD, J. Greg Slatter, PhD, Sergey Aksenov, PhD, Nidal Al-Huniti, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4997.
https://doi.org/10.1182/blood.V130.Suppl_1.4997.4997
Published: 2017
Journal Articles

Phase IA/II Study of Oral LBH589, a Novel Deacetylase Inhibitor (DACi), Administered on 2 Schedules, in Patients with Advanced Hematologic Malignancies.

Andrew Spencer, MD, Miles Prince, MD, Daniel J. DeAngelo, MD, Thomas Fischer, MD, Kapil N. Bhalla, MD, Francis J. Giles, MB, MD, FRCPI, FRCPa, Angela Liu, PharmD, Kathryn Parker, PhD, Glen Laird, PhD, Eric Masson, PharmD, John Rediske, PhD, Jeffrey W. Scott, PhD, Oliver G. Ottmann, MD
Journal: Blood
Blood (2007) 110 (11): 907.
https://doi.org/10.1182/blood.V110.11.907.907
Published: 2007